share_log

Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary

Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary

2022年9月8日的重要生物技术催化剂-当天结束摘要
Benzinga Real-time News ·  2022/09/08 18:18
The United States Food and Drug Administration (FDA) has approved Revance Therapeutics' (NASDAQ:RVNC) lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of moderate to severecfrown lines (glabellar lines) in adults. Revance shares traded as high as 22.39 percent, in a range of $22.02 to $25.47 on day volume of 8.73 million shares versus three months average volume of 729.3 thousand shares, closed regular trading session at $25.30.
美国食品和药物管理局(FDA)已经批准瑞恩斯治疗公司‘(纳斯达克股票代码:RVNC)注射用铅资产DAXXIFY(达西肉毒毒素A-LAMM),用于暂时改善成年人中度至严重皱眉纹(眉间皱纹)。Revance的股价高达22.39%,在22.02美元至25.47美元的范围内,当日成交量为873万股,而三个月平均成交量为72.93万股,收盘时常规交易时段为25.30美元。
Silence Therapeutics (NASDAQ:SLN) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead candidate SLN124 for the treatment of polycythemia vera (PV). Silence Therapeutics shares traded as...
沉默疗法纳斯达克(Sequoia Capital:SLN)宣布,美国食...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发